gnidrologs (![[info]](http://klab.lv/img/userinfo.gif){kind=small} gnidrologs) rakstīja,@ 2022-09-13 10:01:00 |
 |
 |
 |
|
|
|
|
|
|
 |
|
 |
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
"3.4. Harm-benefit considerations
In the Moderna trial, the excess risk of serious AESIs (15.1 per 10,000 participants) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (6.4 per 10,000 participants). [3] In the Pfizer trial, the excess risk of serious AESIs (10.1 per 10,000) was higher than the risk reduction for COVID-19 hospitalization relative to the placebo group (2.3 per 10,000 participants)."